The study involves comparing the effects of bimekizumab (also referred to as BZK) and adalimumab (also referred to as ADA). Bimekizumab is a medication that works by blocking two specific proteins in the body that contribute to inflammation. The participants will receive one of these two treatments through an injection. During the course of the study, the way these medications manage pain and inflammation in the spine and chest area will be observed over several months.

Participants in this research will be given upadacitinib, which is an oral medication taken in the form of a prolonged-release tablet. This type of pill is designed to release the medicine slowly into the body over time. The study will follow the participants over a period of 52 weeks to observe how frequently episodes of eye inflammation occur while taking the medication.

The purpose of this study is to see if SPY072 can reduce disease activity in people with these three types of rheumatologic disease and to check if the medication is safe. The study will measure how well SPY072 works by looking at different aspects of disease activity. For rheumatoid arthritis, the study will check changes in disease activity at week 12. For axial spondyloarthritis and psoriatic arthritis, measurements will be taken at week 16. The study will also look at how many participants show improvement in their symptoms and will measure the levels of the medication in the blood.

During the study, participants will receive treatment for up to 40 weeks. The study will monitor participants for any unwanted effects or problems that might occur with the medication. The study will also check if the body develops any immune response to the medication. Different measurements will be used depending on which type of rheumatologic disease the participant has, but all are designed to see if the medication helps reduce joint pain, swelling, and other symptoms of the disease.

The purpose of this research is to determine if gradually reducing the dose of these medications is as effective as continuing with the current dose in patients whose disease is well-controlled. The study will examine patients who have maintained low disease activity or whose symptoms have been in remission for at least 6 months while taking these medications.

During the 12-month study period, participants will be monitored for disease activity, quality of life, and any side effects. The study will track how well the joints function, any disease flare-ups, and other health-related factors. Researchers will also measure medication levels in the blood and examine immune system cells to better understand how these treatments work.

The study will collect breast milk samples from mothers who are already receiving bimekizumab treatment as prescribed by their doctor. Samples will be taken over a period of two weeks, with additional samples collected depending on how often the participant receives their medication. The main purpose is to measure the amount of medication that passes into breast milk.

Participants must be at least 18 years old, currently breastfeeding, and have been receiving bimekizumab treatment for at least 12 weeks after giving birth. The study will monitor both mothers and infants for any side effects throughout the study period. The medication dose and schedule will continue as previously prescribed by the participant’s doctor.

The purpose of the study is to evaluate how well Upadacitinib can reduce symptoms such as inflammation and pain in the spine and joints of patients with active symptoms of these conditions. Participants will take the medication or placebo orally in the form of a modified-release tablet. The study will last for a period of 24 weeks, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI (Magnetic Resonance Imaging), to measure inflammation in the spine and joints. The study aims to provide valuable information on the effectiveness of Upadacitinib in managing symptoms of Psoriatic Arthritis and Axial Spondyloarthritis, potentially offering a new treatment option for individuals affected by these conditions.

The purpose of this research is to determine if the new imaging tracer can work as well as or better than the current standard method in detecting and evaluating inflammatory conditions. The study will look at how well each tracer can identify the source of unexplained fever and inflammation, assess the extent of IgG4-related disease (a condition that can affect multiple organs), and distinguish between inflammatory and mechanical back pain in patients with spine problems.

During the study, participants will receive an intravenous injection of the imaging tracer before undergoing the PET/CT scan. Some participants may need to have two scans, particularly those with spine conditions who will be evaluated before and after three months of treatment. The maximum amount of tracer used for each scan will be 100 MBq, with a total maximum dose of 550 MBq over the entire study period.

Participants in the study will receive Sonelokimab through a subcutaneous injection, which means it is injected under the skin. Additionally, a special imaging agent called 68Ga-FAPI-46 will be used to help visualize the inflammation in the body. This agent is injected and then detected using a scan called FAPI-PET/CT, which combines positron emission tomography and low-dose computed tomography to create detailed images of the body’s internal structures.

The purpose of the study is to assess changes in disease activity over a period of 12 weeks. Participants will undergo regular imaging scans to monitor the effects of the treatment. The study will help researchers understand how Sonelokimab impacts inflammation in the joints and spine, potentially leading to better treatment options for people with these conditions.

The purpose of the study is to determine which treatment is more effective in achieving low disease activity in patients who have not responded well to NSAID therapy in outpatient care. Participants will receive either high-dose NSAID therapy or direct treatment with a TNF blocker. The study will last for a period of 24 weeks, during which the participants’ disease activity will be monitored at various intervals. The effectiveness of the treatments will be assessed by measuring the level of disease activity using a specific scale known as the Ankylosing Spondylitis Disease Activity Score (ASDAS).

Throughout the study, participants will undergo regular assessments, including MRI scans to check for inflammation in the spine and sacroiliac joints. The study aims to compare the proportion of patients who achieve low disease activity after 12 weeks of treatment, as well as other measures of improvement over the 24-week period. The study will also monitor any side effects or adverse events that may occur during the treatment. This research will help to better understand the potential benefits and risks of using NSAIDs versus TNF blockers in managing axial spondyloarthritis.

Participants in the study will receive the treatment over a period of 28 weeks. During this time, the effects of the medication on their disease activity will be closely monitored. The study will also include a comparison with a placebo to better understand the treatment’s effectiveness. After the treatment period, participants will be observed for an additional period to see if the benefits of the treatment continue even after it is stopped. The study aims to determine if the treatment can lead to a significant reduction in disease activity and improve the overall health and function of the participants.

Throughout the study, various assessments will be conducted, including MRI scans to evaluate changes in inflammation and other symptoms. The study will also measure improvements in the participants’ ability to perform daily activities and their overall quality of life. The results will help determine if Skyrizi can provide a meaningful improvement in managing very early axial spondyloarthritis and potentially modify the course of the disease.

Participants in the study will receive Sonelokimab through a subcutaneous injection, which means it is injected under the skin. The study will monitor changes in inflammation using a special imaging technique called a positron emission tomography (PET) scan. This scan helps visualize the activity of the disease in the spine and sacroiliac joints, which are located in the lower back. The study will last for a period of 12 weeks, during which participants will undergo regular assessments to track any changes in their condition.

The trial aims to gather information on how well Sonelokimab works in reducing the symptoms of axial spondyloarthritis and to observe any potential side effects. By the end of the study, researchers hope to better understand the effectiveness of this treatment in managing the disease and improving the quality of life for those affected by it.

Participants in the study will receive the medication Ixekizumab and will be monitored over a period of time to observe changes in their pain levels. The study will use a technique called fMRI (functional Magnetic Resonance Imaging) to detect changes in brain activity related to pain. This imaging method helps researchers understand how the medication affects the brain’s response to pain. The study will compare brain activity before and after treatment with Ixekizumab to see if there are any significant changes.

Throughout the study, participants will receive regular injections of Ixekizumab and will undergo fMRI scans at specific intervals. The study aims to provide insights into the effectiveness of Ixekizumab in managing pain associated with axial spondyloarthritis, potentially offering a new treatment option for individuals living with this condition. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in the study will receive either the FMT treatment or a placebo, which is a capsule that looks like the treatment but contains no active ingredients. The FMT treatment is given in the form of a prolonged-release capsule called MaaT033, which contains pooled allogeneic fecal microbiota. The study will also use a product called MOVIPREP, an osmotic laxative that helps clear the intestines, to prepare participants for the FMT procedure. MOVIPREP is an oral solution containing ingredients like ascorbic acid (vitamin C), sodium ascorbate, potassium chloride, sodium chloride, sodium sulfate anhydrous, and macrogol 3350.

The trial will last for several months, during which participants will be monitored to assess the effectiveness of FMT in improving their symptoms. The study will compare the results of those receiving the FMT treatment with those receiving the placebo to determine if there is a significant difference in outcomes. The goal is to see if FMT can correct an imbalance in gut bacteria and improve the clinical condition of patients with axial spondyloarthritis.

The purpose of this research is to examine how ixekizumab affects inflammation throughout the entire body, including joints and areas where tendons and ligaments attach to bones. The medication will be administered as a solution for injection, with participants receiving up to 160 mg per day. The study will use special imaging techniques including MRI (magnetic resonance imaging) and CT (computed tomography) scans to monitor the effects of treatment.

The study will last for two years, during which participants will receive regular medical evaluations and imaging scans. The research will help understand how effectively the medication reduces inflammation in different parts of the body in people with these conditions. Throughout the study, doctors will monitor how the treatment affects both the spine and other joints in the body.

The purpose of this clinical trial is to find out if continuous treatment with secukinumab is better than a placebo at preventing flare-ups in people who have already seen improvement from the treatment. Participants who have reached a state of remission, meaning their symptoms have improved significantly, will either continue with secukinumab or switch to a placebo to see how well the improvements last over time.

Participants will be randomly assigned to either continue receiving secukinumab or switch to a placebo in a process called “double-blind,” meaning neither the participants nor the researchers know who is receiving which treatment. This helps ensure that the study results are unbiased. The study aims to maintain the positive effects of the treatment and observe how many participants remain flare-free over the study period.

The purpose of the study is to see if Tofacitinib can help achieve remission of the disease, meaning a reduction or disappearance of symptoms, in people with early active axial spondyloarthritis who have not responded well to at least one non-steroidal anti-inflammatory drug (NSAID). The study will last for 16 weeks, during which participants will take the medication or placebo orally, in the form of tablets. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored for changes in their condition, including improvements in back pain and inflammation, as well as any side effects they may experience. The study aims to provide valuable information on whether Tofacitinib can be an effective treatment option for people with this form of arthritis, potentially leading to better management of the disease in the future.

The purpose of the study is to improve the way doctors assess the activity of the disease and predict how well patients will respond to treatment. Participants in the study will receive the treatment and undergo imaging tests to see how the disease is progressing. The study will compare the results of these imaging tests with other standard methods to determine if the new approach provides better information about the disease.

Throughout the study, participants will be monitored for changes in their condition over a period of several weeks. The study aims to see if the new imaging method can help doctors make better treatment decisions and improve outcomes for patients with axial spondyloarthritis. The trial will also look at how the treatment affects patients’ quality of life and overall health.

Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will also include a period where participants who respond well to the treatment will have their medication gradually withdrawn to observe if they can maintain remission, which is a state where symptoms are reduced or disappear.

The trial will be conducted over several weeks, with regular check-ups to monitor the participants’ health and the effects of the medication. The primary goal is to see if Upadacitinib can significantly improve the condition of patients with Axial Spondyloarthritis compared to those who receive the placebo. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

The purpose of the study is to evaluate how well filgotinib works in reducing the signs and symptoms of axial spondyloarthritis. Participants will be randomly assigned to receive either the filgotinib tablets or the placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of time, during which participants will take the tablets orally and attend regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the study, the effectiveness of filgotinib will be assessed by looking at various measures of disease activity and quality of life. These assessments will include changes in pain levels, physical function, and overall well-being. The study aims to provide valuable information about the potential benefits and safety of filgotinib for people living with axial spondyloarthritis. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety during the trial.

The purpose of this study is to assess the long-term safety of Secukinumab in patients who have previously participated in a related study and are believed to benefit from continued treatment. Participants will receive Secukinumab through subcutaneous injections, which means the medication is injected under the skin. The study will continue for a period of up to 104 weeks, during which the safety of the treatment will be closely monitored by healthcare professionals.

Throughout the study, participants will be observed for any serious adverse events (SAEs) or adverse events (AEs), which are any unwanted effects that may occur during treatment. The study is open-label, meaning both the participants and the researchers know which treatment is being administered. This trial is designed to ensure that patients who benefit from Secukinumab can continue to receive it safely, with careful monitoring to manage any potential risks.

The purpose of the study is to assess how safe and tolerable bimekizumab is over a long period. Participants will receive bimekizumab as a solution for injection, which is administered under the skin. The study will monitor participants for any side effects and how well they tolerate the medication. The study will also evaluate the effectiveness of bimekizumab in managing symptoms of the disease over time.

Participants in the study will be observed for changes in their condition at various intervals, such as weeks 28, 52, and 112. The study aims to gather information on the incidence of any adverse events and the overall impact of the treatment on the participants’ quality of life and disease activity. This information will help determine the long-term benefits and risks of using bimekizumab for treating Axial Spondyloarthritis and its related conditions.